Close

Mersana Therapeutics (MRSN) IPO Opens Modestly Lower

June 28, 2017 10:56 AM EDT

Today's IPO for Mersana Therapeutics (NASDAQ: MRSN) opened for trading at $14.25 after pricing 5,000,000 shares of common stock at a public offering price of $15.00 per share.

J.P. Morgan, Cowen and Leerink Partners acted as book-running managers for the offering. Wedbush PacGrow acted as co-manager for the offering.

Mersana Therapeutics is a clinical-stage biotechnology company with highly differentiated and proprietary ADC platforms that allow for significantly higher drug loads, with the potential to provide greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead product candidate, XMT-1522, is in Phase I clinical trials. We expect that our second product candidate, XMT-1536, will be entering clinical trials in early 2018. In addition, our partners are advancing their pipeline of ADCs using our platform.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

IPOs

Related Entities

JPMorgan, Cowen & Co, IPO